MYCN and glioblastoma: The differences in which genes are cobound by N-MYC and WDR5 may need to be considered when thinking about the outcome of targeting WDR5 with small molecules—an approach that has gained attention over the past several years [35–38]—and most recently has been shown to be effective as a potential therapy for disrupting cancer stem cell function in glioblastoma [13].